Please login to the form below

Not currently logged in
Email:
Password:

Otezla

This page shows the latest Otezla news and features for those working in and with pharma, biotech and healthcare.

Celgene to launch five new products through to 2020

Celgene to launch five new products through to 2020

The statements came as Celgene reported expectation-topping sales and earnings driven by Revlimid (lenalidomide) and new psoriasis therapy Otezla (apremilast). ... Looking at the quarterly figures, the standouts were Revlimid’s 18% gain, a 23% rise for

Latest news

More from news
Approximately 6 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    This has been in the pipeline for some time and will face its first major sales and marketing test in Europe with the anticipated launch next year of Otezla (apremilast) for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics